Evidence map›Paper›PMID 36743515›Full record

ArticleBioMed research international2023

Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model.

Otman Siregar, Aznan Lelo, Ahmad Jabir Rahyussalim, Syafruddin Ilyas, Benny, Tri Kurniawati, Yohanes Augustinus, Hendra, Tommy Mandagi, Muhammad Luqman Labib Zufar and 1 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Otman SiregarDepartment of Orthopaedics and Traumatology, Adam Malik General Hospital, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.ORCID https://orcid.org/0000-0002-3009-0970
Aznan LeloDepartment of Pharmacology and Therapeutics School of Medicine, Universitas Sumatera Utara, Indonesia.ORCID https://orcid.org/0000-0002-3360-0120
Ahmad Jabir RahyussalimDepartment of Orthopaedics and Traumatology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID https://orcid.org/0000-0003-3248-1147
Syafruddin IlyasDepartment of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia.ORCID https://orcid.org/0000-0003-2760-2901
BennyDepartment of Orthopaedics and Traumatology, Adam Malik General Hospital, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.ORCID https://orcid.org/0000-0001-9516-4160
Tri KurniawatiStem Cell and Tissue Engineering Cluster, IMERI Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID https://orcid.org/0000-0001-7185-2356
Yohanes AugustinusDepartment of Orthopaedics and Traumatology, Adam Malik General Hospital, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.ORCID https://orcid.org/0000-0002-3290-8828
HendraDepartment of Orthopaedics and Traumatology, Adam Malik General Hospital, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.ORCID https://orcid.org/0000-0002-3321-9071
Tommy MandagiDepartment of Orthopaedics and Traumatology, Adam Malik General Hospital, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.ORCID https://orcid.org/0000-0001-5579-5320
Muhammad Luqman Labib ZufarMedical graduate, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID https://orcid.org/0000-0002-1286-0273
Irfan FathurrahmanMedical graduate, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.ORCID https://orcid.org/0000-0001-5636-8507
Universitas Sumatera Utara · IDUniversity of Indonesia · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis (TB) of the spine is a highly disruptive disease, especially in underdeveloped and developing countries. This condition requires standard TB treatment for 9-18 months, which increases patient risk of drug-resistant TB. Consequently, this raises the concern of adopting additional therapies to shorten the treatment duration, improve the efficacy of anti-TB drugs, and further decrease damage in the affected tissues and organs. Matrix metalloproteinase- (MMP-) 1 is a key regulator of the destruction of the extracellular matrix and associated proteins and is a new potential target for TB treatment research. In the present study, we investigated the effects of doxycycline as an MMP-1 inhibitor in patients with spondylitis TB. Methods: Seventy-two New Zealand white rabbits with spondylitis TB were divided into 12 different groups based on incubation period (2, 4, 6, and 8 weeks) and doxycycline administration (without, 1 mg/kg body weight (BW), and 5 mg/kg BW). We observed the course of infection through the blood concentration changes and immunohistochemical examination of MMP-1, in addition to BTA staining, culture, polymerase chain reaction (PCR), and histopathological examination. Results: Treatment with once daily 5 mg/kg BW doxycycline significantly improved the blood MMP-1 level ( Conclusion: Our study demonstrated the potential of doxycycline as an adjunctive treatment in spondylitis TB. However, limitations remain regarding the differences in the pathogenesis and virulence of

Indexed as

DoxycyclineMatrix Metalloproteinase InhibitorsSpondylitisTuberculosisAnimalsHumansMatrix Metalloproteinase 1Mycobacterium tuberculosisRabbitsDoxycyclineMatrix Metalloproteinase 1Matrix Metalloproteinase Inhibitors

Identifiers

PMID36743515
PMCPMC9897918
OpenAlexW4318306725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.